3 minute read

In this article:

• What was wrong with the old name?
• What does PMOS actually mean?
• How does this link with skin?
• Why does this matter for women in the real world?
• A precedent worth setting
• What we have always believed at Equi

If you have ever been told you have PCOS — or spent years wondering whether you might — there is something important to know. The name has just changed. And the reason it changed matters far more than the name itself.

But this is not just a story for women with PCOS (or the newly named PMOS). It is a story about women's health more broadly — about how long it has taken medicine to recognise the full complexity of the female body, and about what happens when conditions are named, framed, and researched too narrowly. If you are a woman who has ever felt dismissed by a GP, told your results were normal when something clearly was not, or found that no single diagnosis quite captured what you were experiencing, then this blog post is relevant to you too.

Polycystic ovary syndrome (PCOS), a condition affecting more than 170 million women worldwide, has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS), following a landmark global consensus study published in The Lancet. The process involved over 22,000 people — patients, clinicians, researchers, and advocates across multiple countries — and took more than a decade to complete.¹ The fact that it took that long to rename a condition affecting one in eight women says something in itself.

What was wrong with the old name?

The name polycystic ovary syndrome implied that the condition was primarily about ovarian cysts. Many patients do not have ovarian cysts at all, and yet the name reduced a complex, long-term hormonal disorder to a misunderstanding about cysts and an overt focus on the ovaries. This contributed to missed diagnoses and inadequate treatment for millions of women whose symptoms did not fit the expected picture.

But the confusion ran in both directions. Some women did have cysts visible on ultrasound, and experienced real hormonal symptoms, yet still could not receive a diagnosis, because without the accompanying androgen imbalances that form part of the diagnostic criteria, the picture was deemed incomplete. Having cysts was neither sufficient for a diagnosis, nor necessary for the condition to be present.

Many women struggling may have been told that their bloods looked normal, or that it was just their weight. Some may have also been told that they should come back when they were trying to conceive. The name, in part, enabled that dismissal because if the condition is defined by ovarian cysts, and you do not have visible cysts, it is easy for the system to look elsewhere.

What does PMOS actually mean?

The new name breaks down into three meaningful parts.

• Polyendocrine recognises that the condition is underpinned by multiple interacting hormonal disturbances — including insulin, androgens, and neuroendocrine hormones, rather than being an isolated ovarian disorder.
• Metabolic acknowledges the inherent metabolic features such as insulin resistance and increased risks for type 2 diabetes and cardiovascular disease.
• Ovarian retains the connection to ovarian dysfunction, including ovulatory disturbances

In other words, the new name reflects what women with this condition have always known — that it affects far more than the ovaries. It affects the skin, the metabolism, the hormonal system, energy levels, mood, fertility, cardiovascular health, and the way the body responds to insulin. For too long, the name reduced a complex, long-term hormonal disorder to a misunderstanding about cysts and a focus on the ovaries. PMOS corrects that.

How does this link with skin?

Skin is a particularly telling example of this. Many women with PMOS experience acne, oiliness, skin darkening in skin folds (a sign of insulin resistance known as acanthosis nigricans), and excess facial hair — all of which are direct manifestations of the androgen excess and insulin dysregulation that sit at the heart of the condition. Yet because these symptoms appear on the surface, they are frequently addressed at the surface with topical treatments, prescriptions, and aesthetic interventions, without anyone investigating the internal hormonal and metabolic environment driving them.

This is something we feel strongly about at Equi. Skin that is reacting (whether through acne, sensitivity, or texture changes) is rarely just a skin problem. In the context of PMOS, it is the hormonal and metabolic system expressing itself visibly. Addressing it meaningfully requires looking inward, not just outward. It is one of the reasons we are so passionate about the inside-out approach to skin health, and why we have formulated specifically to support the hormonal, gut, and inflammatory pathways that determine how skin behaves. For women with PMOS, this is not just a wellness consideration — it can be life-changing.

Why does this matter for women in the real world?

A name change in a medical journal might seem abstract. But language shapes how conditions are understood, diagnosed, and treated — by doctors, by patients, and by the systems that fund research and care.

When a condition is named after one of its least universal features, women spend years being told they do not have it. When a condition is framed as gynaecological rather than metabolic and endocrine, the treatment options offered are narrower than they should be. When the full picture is not reflected in the name, the full picture is less likely to be investigated.

The shift to PMOS opens the door to earlier diagnosis, better metabolic investigation, and a broader clinical conversation about what women with this condition actually need — including nutritional support for insulin sensitivity, hormonal balance, and inflammation, all of which sit at the heart of what PMOS involves.

A precedent worth setting

PMOS is not the only condition where the medical framing has failed to keep pace with the reality of what women experience. Endometriosis is another example that comes to mind — a condition historically categorised as a gynaecological disorder, yet one whose reach extends far beyond the reproductive system. Women with endometriosis report systemic symptoms including fatigue, immune dysregulation, gastrointestinal involvement, and heightened inflammatory responses throughout the body. Growing research points to links between endometriosis and autoimmunity, gut permeability, and microbiome disruption — connections that a purely gynaecological framing has consistently obscured and underfunded.^2,3

Both conditions are a reminder that women's health has too often been reduced to reproductive function alone — and that when the framing is too narrow, the research questions asked, the diagnostic criteria applied, and the treatments offered all become too narrow with it.

We hope the renaming of PMOS sets a meaningful precedent. That it signals a broader shift in how medicine approaches conditions that are complex, multi-system, and disproportionately affect women. That it opens the door to more joined-up thinking about the relationships between hormones, immunity, metabolism, gut health, and long-term wellbeing — and that women who have spent years being told their symptoms do not quite fit finally find themselves at the centre of a more complete conversation.

What we have always believed at Equi

This renaming reflects something we have understood since we started formulating. Women's hormonal health is systemic. It does not sit neatly in one organ or one pathway. PMOS involves the gut, the liver, the adrenal glands, blood sugar regulation, and the inflammatory environment — as well as the ovaries.

It is why our approach to formulation has always addressed multiple systems simultaneously rather than targeting single symptoms. And it is why we welcome this shift in the medical community's understanding — not because it validates us, but because it may mean that the women who have been dismissed, misdiagnosed, or undertreated for years finally get the recognition and care they deserve.

If you have been told you have PCOS/PMOS and want to understand how nutritional support can play a role in managing the underlying hormonal and metabolic picture, we are here to help. Our formulas are not a treatment for PMOS, but they are formulated by a registered nutritional therapist with deep experience in exactly this area. Take our quiz to find the right starting point for you HERE.

This article is for informational purposes only and does not constitute medical advice. If you have been diagnosed with PMOS or are experiencing symptoms associated with this condition, please speak to your GP or a qualified healthcare professional.

References

1. Teede HJ, Bahri Khomami M, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026. doi:10.1016/S0140-6736(26)00717-8.
2. Sinaii N, Cleary SD, Ballweg ML, et al. High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis. Hum Reprod. 2002;17(10):2715–2724.
3. Ek M, Roth B, Ekström P, et al. Gastrointestinal symptoms among endometriosis patients — a case-cohort study. BMC Womens Health. 2015;15:59.